|
Lyn Wiesinger became a director at Hana in March 2007. Ms. Wiesinger has more than 20 years of pharmaceutical operating experience in both global and US marketing new product development business acquisitions and licensing. Most recently she was Senior Vice President of Marketing and Market Development at Vicuron Pharmaceuticals a biotechnology company in the specialty hospital market where she initiated and led the company’s commercial function. She subsequently played an integral role in Vicuron’s sale to Pfizer Inc. in September 2005. Prior to joining Vicuron Ms. Wiesinger held senior positions at Bristol-Myers Squibb including Vice President US Cardiovascular Marketing where she lead the pre-launch program and marketing team for Vanlev a novel antihypertensive and CHF treatment and Vice President Global Marketing Infectious Diseases where she was responsible for managing the company’s worldwide portfolio of antibiotics antivirals and antifungals. Ms. Wiesinger established her early career in pharmaceuticals with an extensive tenure at Pfizer Inc. during which she held a broad range of management positions in new product development and marketing marked by her leadership of the successful worldwide development and launch of Diflucan. Ms Wiesinger began her career as a consultant at Booz Allen and Hamilton. She holds an MBA degree from the Wharton School and a BA degree in psychology from the University of Pennsylvania. She is a member of the Board of Trustees of the National Foundation of Infectious Diseases the Advisory Board of the Philadelphia University of the Sciences and a Director of the Wellness Community of Philadelphia. | 